Egyptian International Pharmaceutical Industries Company (EGX:PHAR)
Egypt · Delayed Price · Currency is EGP 88.00
+1.14 (1.31%)
At close: Jun 4, 2026
EGX:PHAR Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,674 | 9,441 | 7,591 | 5,232 | 3,955 | 3,409 | |
Revenue Growth (YoY) | 15.34% | 24.38% | 45.09% | 32.27% | 16.03% | 18.13% |
Cost of Revenue | 5,511 | 5,300 | 4,244 | 2,983 | 2,397 | 1,957 |
Gross Profit | 4,164 | 4,141 | 3,346 | 2,248 | 1,558 | 1,452 |
Selling, General & Admin | 1,266 | 1,248 | 1,127 | 788.09 | 683.2 | 566.08 |
Research & Development | 71.85 | 70.94 | 70.46 | 43.23 | 43.68 | 34.96 |
Other Operating Expenses | 110 | 105 | 312.01 | 167.2 | 134.35 | 60.79 |
Operating Expenses | 1,824 | 1,800 | 1,839 | 1,038 | 896.23 | 674.83 |
Operating Income | 2,340 | 2,341 | 1,507 | 1,211 | 662 | 776.85 |
Interest Expense | -1,252 | -1,275 | -928.54 | -388.52 | -195.42 | -136.25 |
Interest & Investment Income | 118.08 | 139.67 | 72.05 | 26.24 | 57.77 | 32.11 |
Earnings From Equity Investments | 495.5 | 495.5 | 147.11 | 74.51 | - | - |
Currency Exchange Gain (Loss) | -36.29 | -16.17 | 699.88 | 139.63 | 286.4 | -6.25 |
Other Non Operating Income (Expenses) | 68.08 | 84.46 | 11.04 | 1.51 | -20.62 | -24.04 |
EBT Excluding Unusual Items | 1,733 | 1,769 | 1,509 | 1,064 | 790.13 | 642.41 |
Gain (Loss) on Sale of Assets | 4.58 | 1.76 | 0.22 | 4.69 | 3.7 | 2.78 |
Pretax Income | 1,737 | 1,771 | 1,509 | 1,069 | 793.83 | 645.19 |
Income Tax Expense | 313.87 | 313.04 | 411.83 | 245.62 | 150.07 | 156.9 |
Earnings From Continuing Operations | 1,424 | 1,458 | 1,097 | 823.31 | 643.76 | 488.29 |
Minority Interest in Earnings | -16.52 | -16.24 | -1.21 | -0.99 | -0.78 | -0.53 |
Net Income | 1,407 | 1,442 | 1,096 | 822.32 | 642.98 | 487.75 |
Net Income to Common | 1,407 | 1,442 | 1,096 | 822.32 | 642.98 | 487.75 |
Net Income Growth | 73.51% | 31.57% | 33.25% | 27.89% | 31.83% | 0.25% |
Shares Outstanding (Basic) | 167 | 162 | 149 | 149 | 99 | 99 |
Shares Outstanding (Diluted) | 167 | 162 | 149 | 149 | 99 | 99 |
Shares Change (YoY) | 12.11% | 8.91% | - | 50.00% | - | 1.64% |
EPS (Basic) | 8.44 | 8.90 | 7.37 | 5.53 | 6.48 | 4.92 |
EPS (Diluted) | 8.44 | 8.90 | 7.37 | 5.53 | 6.48 | 4.92 |
EPS Growth | 54.76% | 20.80% | 33.25% | -14.74% | 31.83% | -1.36% |
Free Cash Flow | -1,563 | -261.15 | -4,121 | -2,198 | -859.77 | -53.27 |
Free Cash Flow Per Share | -9.37 | -1.61 | -27.70 | -14.77 | -8.67 | -0.54 |
Dividend Per Share | - | - | 1.500 | 1.000 | 1.000 | 1.500 |
Dividend Growth | - | - | 50.00% | - | -33.33% | - |
Gross Margin | 43.04% | 43.86% | 44.08% | 42.98% | 39.40% | 42.59% |
Operating Margin | 24.19% | 24.80% | 19.85% | 23.14% | 16.74% | 22.79% |
Profit Margin | 14.54% | 15.27% | 14.44% | 15.72% | 16.26% | 14.31% |
Free Cash Flow Margin | -16.16% | -2.77% | -54.29% | -42.01% | -21.74% | -1.56% |
EBITDA | 2,478 | 2,450 | 1,607 | 1,314 | 759.39 | 867.73 |
EBITDA Margin | 25.61% | 25.96% | 21.18% | 25.12% | 19.20% | 25.46% |
D&A For EBITDA | 137.85 | 109.46 | 100.45 | 103.17 | 97.39 | 90.88 |
EBIT | 2,340 | 2,341 | 1,507 | 1,211 | 662 | 776.85 |
EBIT Margin | 24.19% | 24.80% | 19.85% | 23.14% | 16.74% | 22.79% |
Effective Tax Rate | 18.07% | 17.68% | 27.30% | 22.98% | 18.90% | 24.32% |